Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

Treatment options for patients with metastatic colorectal cancer (mCRC) are limited. This particularly affects the largest group of patients with RAS mutations, who are considered ineligible for therapy with antiEGFR antibodies. In this liquid biopsy-based study, we performed the first in-depth anal...

Full description

Bibliographic Details
Main Authors: Susanne Klein-Scory, Ingo Wahner, Marina Maslova, Yosef Al-Sewaidi, Michael Pohl, Thomas Mika, Swetlana Ladigan, Roland Schroers, Alexander Baraniskin
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Oncology
Subjects:
digital droplet PCR
BEAMing
colorectal cancer
clonal selection
neoRAS wild-type
liquid biopsy
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01115/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01115/full

Similar Items